Stage IV cervical vaccine

HPV vaccine can prevent some HPV virus infection and reduce the risk of cervical cancer and precancerous lesions.

HPV vaccine can prevent specific types of HPV virus. HPV vaccine mainly targets HPV6, 11, 16 and 18. HPV16 and 18 are the main high-risk viruses that cause cervical cancer, while HPV6 and 11 are associated with diseases such as condyloma acuminatum. Vaccination can produce antibodies in advance and play a role in resisting virus infection. It is

generally recommended that women aged 20 to 45 receive HPV vaccine. In this age group, vaccination can better play its preventive role. Of course, the specific vaccination age needs to be based on individual conditions and doctor's recommendations. After rigorous clinical trials and years of practical application, the safety of HPV vaccine is guaranteed. Cervical

cancer can be prevented by vaccination. However, it is important to take into account age, health status and other factors, and follow the doctor's advice. At the same time, it is necessary to recognize the limitations of the vaccine, continue to maintain good living habits and regular cervical cancer screening to better protect women's health.